Text Size

Schizophrenia Sensory Gating Deficit With Quetiapine

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
New Mexico VA Healthcare System
ClinicalTrials.gov Identifier:
NCT00536783
First received: September 27, 2007
Last updated: December 20, 2007
Last verified: September 2007
History of Changes
  Purpose

The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after three months of taking the antipsychotic medication quetiapine.


Condition Intervention
Schizophrenia
 Drug: Quetiapine

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Schizophrenia Sensory Gating Deficit With Quetiapine

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by New Mexico VA Healthcare System:

Estimated Enrollment: 20
Study Start Date: April 2004
Study Completion Date: March 2006
Detailed Description:

.Problems with attention and perception are core features of schizophrenia and are hypothesized to result from defects in the filtering or gating of sensory input. Examination of this requires neuoimaging techniques with high temporal resolution. High-density EEG and MEG in combination with structural magnetic resonance imaging (sMRI) are used to map sensory gating. In a number of recent studies patient treated with novel antipsychotics have been shown to have P50 gating ratios resembling those of normal controls rather than that of schizophrenia subjects treatment with conventional antipsychotics. To date, there is no literature on the effects of quetiapine on sensory gating. Subjects who meet all inclusion criteria and have been on a stable dose of quetiapine for three months will receive a clinical interview, an MRI, MEG, and neuropsychological testing to determine if patients with schizophrenia who are treated with quetiapine will demonstrate a sensory gating ratio similar to normal controls, indicating no deficit in sensory gating.

  Eligibility

Ages Eligible for Study:   18 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Patient Population

  • Diagnosis of Schizophrenia as determine by the Structured Clinical Interview for DSM-IV
  • No comorbid diagnosis of PTSD
  • responders to quetiapine, determined by continuous treatment at the same dose of quetiapine and absence of psychiatric hospitalization for at least 3 months
  • No history of drug dependency in their lifetime
  • No history of alcohol or other substance abuse in the 6 months prior to entry into the study
  • No history of head injury with loss of consciousness for more than 5 minutes
  • No history of seizure disorder
  • No mood stabilizing agents
  • Between 18-65 and
  • Able to sign informed consent

Normal Controls

  • Matched in age and gender to patient population
  • No history of psychiatric dysfunction or alcohol or other substance dependence in their lifetime as determine by the SCID
  • No history of alcohol or other substance abuse in the previous 6 months
  • No family history of psychotic disorder in first degree relatives as assessed by the FH-RDC diagnostic interview
  • No history of head injury with loss of consciousness for more than 5 minutes
  • No history of seizure disorder
  • Between 18-65
  • Able to sign informed consent

Exclusion Criteria:

Subjects will be excluded from participating in this study if they:

  • Require treatment with a mood stabilizer
  • Have had an inpatient hospitalization in the past 3 months
  • Have a history of a neurological disorder
  • Have any other axis I diagnosis besides schizophrenia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00536783

Locations
United States, New Mexico
New Mexico VA Healthcare System
Albuquerque, New Mexico, United States, 87108
Sponsors and Collaborators
New Mexico VA Healthcare System
AstraZeneca
Investigators
Principal Investigator: Jose M Canive, MD New Mexico VA Heathcare System / BRINM
  More Information

Additional Information:
The New Mexico VA Healthcare System website  This link exits the ClinicalTrials.gov site
The website for the University of New Mexico Human Research Review Committee which oversees the protection of human subjects for this project.  This link exits the ClinicalTrials.gov site
The website for the Biomedical Research Institute of New Mexico which helps administers the funds for this project.  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00536783     History of Changes
Other Study ID Numbers: 0072, . IRUSQUET0332
Study First Received: September 27, 2007
Last Updated: December 20, 2007
Health Authority: United States: Federal Government

Keywords provided by New Mexico VA Healthcare System:
Psychiatry
Antipsychotic
Psychopharmacology
Clinical Trial
Open Label
 Schizophrenia
Sensory Gating
Attention
Memory

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
 Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 22, 2013